Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is poised for success with their innovative test, EsoGuard, that has already gained attention and positive coverage from payers. The company is also expanding their market to include higher-risk patients and has received grant funding for research in non-GERD patients, showing the potential for further growth. With a "Buy" rating from a reputable investment firm and promising results, Lucid has a positive outlook for the future.

Bears say

Lucid Diagnostics is a commercial-stage medical diagnostics technology company that focuses on patients at risk of developing esophageal cancer. The company's two main products, EsoGuard and EsoCheck, are expected to receive positive coverage from Medicare in mid-2026, which will likely serve as a catalyst for ramping up commercialization and revenue growth. With multiple growth drivers ahead, including potential commercial payor wins and increased Medicare coverage, Lucid Diagnostics has the potential for significant market growth in the expanding field of esophageal cancer detection.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Jul 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.